From Arthritis & Rheumatic Disease Specialties, Aventura, FL.
The author is a member of the Speakers’ Bureau for and received a grant for the development of this paper from Centocor. He also receives funding for clinical research from Bristol Myers Squibb, Eli Lily, AstraZeneca, UCB, Roche, Genentech, Celgene, Human Genome Sciences, and Cephalon.
The author declares no conflict of interest.
Correspondence: Norman B. Gaylis, MD, Arthritis & Rheumatic Disease Specialties, 21097 NE 27th Court, Suite 200, Aventura, FL 33180. E-mail: [email protected].
doi: 10.1097/RHU.0b013e31824e9151